[HTML][HTML] A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments
C Zengarini, A Guglielmo, M Mussi, G Motta… - Antibodies, 2024 - mdpi.com
The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to
its role in impairing immune responses against malignant T-cells and expression profiles …
its role in impairing immune responses against malignant T-cells and expression profiles …